CD36 and hepatocellular carcinoma: Hence, these genes might serve as molecular targets to restrict oncogenic (i.e. ATIC, BZW2) and lipogenic (i.e. CD36, PPARγ), but promote tumor suppressive (i.e. TAGLN2) activity to treat human HCC.